These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 9601508)
1. Adaptation of Theiler's virus to L929 cells: mutations in the putative receptor binding site on the capsid map to neutralization sites and modulate viral persistence. Jnaoui K; Michiels T Virology; 1998 May; 244(2):397-404. PubMed ID: 9601508 [TBL] [Abstract][Full Text] [Related]
2. A neutralization site of DA strain of Theiler's murine encephalomyelitis virus important for disease phenotype. Sato S; Zhang L; Kim J; Jakob J; Grant RA; Wollmann R; Roos RP Virology; 1996 Dec; 226(2):327-37. PubMed ID: 8955052 [TBL] [Abstract][Full Text] [Related]
3. The CD4-mediated immune response is critical in determining the outcome of infection using Theiler's viruses with VP1 capsid protein point mutations. Rodriguez M; Roos RP; McGavern D; Zoecklein L; Pavelko K; Sang H; Lin X Virology; 2000 Sep; 275(1):9-19. PubMed ID: 11017783 [TBL] [Abstract][Full Text] [Related]
4. The structure of a highly virulent Theiler's murine encephalomyelitis virus (GDVII) and implications for determinants of viral persistence. Luo M; Toth KS; Zhou L; Pritchard A; Lipton HL Virology; 1996 Jun; 220(1):246-50. PubMed ID: 8659122 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the leader and capsid coding regions of persistent and neurovirulent strains of Theiler's virus. Michiels T; Jarousse N; Brahic M Virology; 1995 Dec; 214(2):550-8. PubMed ID: 8553557 [TBL] [Abstract][Full Text] [Related]
6. Mutations that affect the tropism of DA and GDVII strains of Theiler's virus in vitro influence sialic acid binding and pathogenicity. Jnaoui K; Minet M; Michiels T J Virol; 2002 Aug; 76(16):8138-47. PubMed ID: 12134019 [TBL] [Abstract][Full Text] [Related]
7. Efficient infection of buffalo rat liver-resistant cells by encephalomyocarditis virus requires binding to cell surface sialic acids. Guy M; Chilmonczyk S; Crucière C; Eloit M; Bakkali-Kassimi L J Gen Virol; 2009 Jan; 90(Pt 1):187-96. PubMed ID: 19088288 [TBL] [Abstract][Full Text] [Related]
8. The effect of Theiler's murine encephalomyelitis virus (TMEV) VP1 carboxyl region on the virus-induced central nervous system disease. Senkowski A; Shim B; Roos RP J Neurovirol; 1995 Mar; 1(1):101-10. PubMed ID: 9222346 [TBL] [Abstract][Full Text] [Related]
9. Lack of correlation of Theiler's virus binding to cells with infection. McCright IJ; Fujinami RS J Neurovirol; 1997 May; 3 Suppl 1():S68-70. PubMed ID: 9179799 [TBL] [Abstract][Full Text] [Related]
10. Replacement of loop II of VP1 of the DA strain with loop II of the GDVII strain of Theiler's murine encephalomyelitis virus alters neurovirulence, viral persistence, and demyelination. Wada Y; McCright IJ; Whitby FG; Tsunoda I; Fujinami RS J Virol; 1998 Sep; 72(9):7557-62. PubMed ID: 9696853 [TBL] [Abstract][Full Text] [Related]
11. Theiler's murine encephalomyelitis virus (TMEV): the role of a small out-of-frame protein in viral persistence and demyelination. Obuchi M; Ohara Y Jpn J Infect Dis; 1999 Dec; 52(6):228-33. PubMed ID: 10738359 [TBL] [Abstract][Full Text] [Related]
12. UDP-galactose transporter is required for Theiler's virus entry into mammalian cells. Hertzler S; Kallio P; Lipton HL Virology; 2001 Aug; 286(2):336-44. PubMed ID: 11485401 [TBL] [Abstract][Full Text] [Related]
13. [Infection of the mouse by Theiler's virus; a model for the study of demyelinating diseases of the central nervous system]. Brahic M Bull Acad Natl Med; 1996 Feb; 180(2):305-15; discussion 315-6. PubMed ID: 8705377 [TBL] [Abstract][Full Text] [Related]
14. A single amino acid change determines persistence of a chimeric Theiler's virus. Jarousse N; Grant RA; Hogle JM; Zhang L; Senkowski A; Roos RP; Michiels T; Brahic M; McAllister A J Virol; 1994 May; 68(5):3364-8. PubMed ID: 7512164 [TBL] [Abstract][Full Text] [Related]
15. Mutation in loop I of VP1 of Theiler's virus delays viral RNA release into cells and enhances antibody-mediated neutralization: a mechanism for the failure of persistence by the mutant virus. McCright IJ; Tsunoda I; Libbey JE; Fujinami RS J Neurovirol; 2002 Apr; 8(2):100-10. PubMed ID: 11935462 [TBL] [Abstract][Full Text] [Related]
16. Theiler's viruses with mutations in loop I of VP1 lead to altered tropism and pathogenesis. McCright IJ; Tsunoda I; Whitby FG; Fujinami RS J Virol; 1999 Apr; 73(4):2814-24. PubMed ID: 10074129 [TBL] [Abstract][Full Text] [Related]
17. Altered cell growth and morphology in a BHK-21 cell mutant that lacks a receptor for Theiler's murine encephalomyelitis virus. Libbey JE; Tsunoda I; Fujinami RS Virology; 2002 Mar; 294(1):85-93. PubMed ID: 11886268 [TBL] [Abstract][Full Text] [Related]
18. A genetic approach to study the pathogenesis of Theiler's virus persistent infection. Azoulay-Cayla A; Brahic M; Bureau JF; Bihl F; Dethlefs S; Fiette L; Jarousse N; Larsson-Sciard EL; Martinat C; McAllister A; Michiels T; Pena Rossi C J Neurovirol; 1997 May; 3 Suppl 1():S55. PubMed ID: 9179795 [No Abstract] [Full Text] [Related]
19. The generation and characterisation of neutralising antibodies against the Theiler's murine encephalomyelitis virus (TMEV) GDVII capsid reveals the potential binding site of the host cell co-receptor, heparan sulfate. Upfold N; Ross C; Bishop ÖT; Luke GA; Knox C Virus Res; 2018 Jan; 244():153-163. PubMed ID: 29155139 [TBL] [Abstract][Full Text] [Related]
20. Role of sialyloligosaccharide binding in Theiler's virus persistence. Zhou L; Lin X; Green TJ; Lipton HL; Luo M J Virol; 1997 Dec; 71(12):9701-12. PubMed ID: 9371636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]